Beware of buzzwords when investing in a new technology, says Derek Lowe at In the Pipeline. He makes fun of an announcement released earlier this year by Primegen, saying that they used carbon nanotubes to reprogram stem cells. Though both are hot fields, they're also still very new. "So what are the odds of getting them to work together? Not as good as the odds that someone thought the combination would make a good press release, I'm afraid," he says.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.